FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative

defense conditions of Rule 10b5-

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(C). Se	ee Instruction 1	0.																		
Name and Address of Reporting Person*     SAHA SAURABH						2. Issuer Name <b>and</b> Ticker or Trading Symbol Centessa Pharmaceuticals plc [ CNTA ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)    Director 10% Owner					
(Last) (First) (Middle) C/O CENTESSA PHARMACEUTICALS PLC 3RD FL., 1 ASHLEY RD, ALTRINCHAM  (Street) CHESHIRE X0 WA14 2DT						3. Date of Earliest Transaction (Month/Day/Year) 12/20/2024  4. If Amendment, Date of Original Filed (Month/Day/Year)									Officer (give title below) Chief Executive Officer  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting					
(City) (State) (Zip)			Zip)											Perso	on					
		Table	I - I	Non-Deriva	tive	Secu	rities	Ac	quir	ed, D	isposed (	of, or	Benefi	cially	Own	ed				
				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		[	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			Benefic Owned		ties Fo cially (D I Following Inc		m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership	
								c	ode	v	Amount	(A) or (D)	Price			ted action(s) 3 and 4)	(Ins	tr. 4)	(Instr. 4)	
Ordinary Shares <sup>(1)</sup>				12/20/2024					<b>S</b> <sup>(2)</sup>		55,000	D	\$17.43	4374(3)		520,661		D		
Ordinary Shares <sup>(1)</sup>														38,000				By trust <sup>(4)</sup>		
		Tal	ole I	II - Derivati (e.g., pu							posed of convert				)wne	d				
1. Title of Derivative Security (Instr. 3)	ive Conversion Date y or Exercise (Month/Day/Year) if		Exe if ar	Deemed cution Date, ry nth/Day/Year)	4. Transaction Code (Instr. 8)		5. Nui of Deriving Securi Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired sed 3, 4	Exp (Mo	oiration inth/Da	y/Year)	Amo Secu Unde Deri Secu 3 and	Amoun or Numbe of	int er		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Benefication Ownership (Instr. 4)	

## **Explanation of Responses:**

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$17.12 to \$17.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 4. These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.

## Remarks:

/s/ Gregory Weinhoff, attorney-in-fact

12/20/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.